Supplementary Material for: Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma

Research output

Research output per year 2019 2019 2019

• 1 Article

Research output per year

Research output per year

Search results

• 2019

  Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma

  Hiraoka, A., Kumada, T., Atsukawa, M., Hirooka, M., Tsuji, K., Ishikawa, T., Takaguchi, K., Kariyama, K., Itobayashi, E., Tajiri, K., Shimada, N., Shibata, H., Ochi, H., Tada, T., Toyoda, H., Nouso, K., Tsutsui, A., Nagano, T., Itokawa, N. & Hayama, K. & 8 others, Imai, M., Joko, K., Tanaka, H., Tamai, T., Koizumi, Y., Hiasa, Y., Michitaka, K. & Kudo, M., 2019/11/01, In: Oncology (Switzerland). 97, 5, p. 277-285 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Tyrosine Kinase Inhibitor 100%
  • Lenvatinib 100%
  • Clinical Factors 100%
  • Unresectable Hepatocellular Carcinoma 100%
  • Sequential Therapy 100%
  75 Scopus citations